Efficacy of Heparin eye drops for management of vernal keratoconjunctivitis: Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-14005386

Enrollment

Unknown

Registered

2014-10-24

Start date

2014-11-07

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy and conjunctivitis

Interventions

Two groups:HyloPARIN eye drops 4 times a day versus Heparin eye drops (Placebo) for 6 weeks

Eligibility

Sex/Gender

All

Age

5 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age 5 years or older; 2. Diagnosed with bilateral vernal keratoconjunctivitis based on the history and clinical examination; 3. Grade 1 (mild, intermittent), grade 2A (moderate, intermittent), grade 2B (moderate, persistent), and grade 3 (severe) VKC.

Exclusion criteria

Exclusion criteria: 1. Age less than 5 years; 2. Grade 4 (very severe), and grade 5 (evolution) VKC; 3. Any other active ophthalmic disease; 4. Pregnancy or breastfeeding; 5. Solid organ transplant recipients; 6. Blood disorders; 7. Hypersensitivity to heparin or related products.

Design outcomes

Primary

Measure	Time frame
Efficacy of heparin eye drops on the objective signs, and ocular symptoms form the Visual Analog Scale;	—

Secondary

Measure	Time frame
Changes in the tear cytokine profile before and after the treatment;Visual acuity outcomes;;Requirement of additional treatment in the form of topical mast cell stabilizers or corticosteroids;;Complications associated with the treatment and disease per se.;	—

Countries

China

Contacts

Public ContactDr. JHANJI Vishal

The Chinese University of Hong Kong

vishaljhanji@cuhk.edu.hk+86 3943 5807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026